Congenital anomalies and spontaneous abortion in mice resulting from the use of escitalopram.

CONTEXT: Escitalopram (ESC) use during pregnancy has not been associated with teratogenic effects in fetuses.

AIMS: To investigate whether ESC administered during pregnancy in mice induces maternal toxicity and teratogenicity in offspring.

METHODS

Treated mice groups G1 and control G0 (n =15 per group). Administration of ESC (G1) and saline solution (G0) during pregnancy and euthanasia on the 18thday. Pregnant female mice were treated with ESC (20mg/kg, via gavage) or saline solution (control group) from the 5th to the 17thday of gestation, when implantation was consolidated. During intraembryonic development until the day before delivery, the drug had an influence on the development of alterations from its maintenance in the uterine environment and its development to the disturbance causing skeletal or visceral malformations.

KEY

RESULTS

The intrauterine development parameters that were altered by ESC treatment were: number of resorptions (G0: [0.93±0.24]); G1: [3.33±0.51]), post-implantation loss (G0: [3.95±1.34], G1: [13.75±3.62]) and reduced fetal viability: [97.30±1.00]; G1: [81.09±6.22]). Regarding fetal formation, the treated group had visceral malformations with a significant frequency: cleft palate (G0: [1.0%], G1: [11.86%]) and reduced kidneys (G0: [0%]; G1: [10.17%]). Regarding skeletal malformations, a higher frequency was observed in the following parameters: incomplete supraoccipital ossification (G0: [0%], G1: [15.25]), absence of ribs (G0: [0%], G1 (G0: [0%], G1 [15.25%]) and absence of one or more of the foot phalanges (G0: [1.0%]; 64%]).

CONCLUSION

Results indicate that ESC is an embryotoxic and teratogenic drug.

IMPLICATIONS: Until further studies are performed, greater caution is necessary in prescribing the drug to pregnant women.